TGA Peptide Enforcement Timeline

The Therapeutic Goods Administration enforces peptide law through the Therapeutic Goods Act 1989, which requires any product claiming therapeutic benefit to be included in the Australian Register of Therapeutic Goods (ARTG) or to be covered by an exemption. The TGA classifies substances through the Poisons Standard (Standard for the Uniform Scheduling of Medicines and Poisons, or SUSMP), which is updated multiple times per year by the Advisory Committee on Chemicals Scheduling. The scheduling determines the legal framework for each substance, from unscheduled (no specific restrictions) through Schedule 4 (prescription only) to Schedule 9 (prohibited except under licence).

Enforcement operations typically involve two agencies working in parallel. The Australian Border Force (ABF) intercepts incoming shipments at airports, postal centres, and cargo facilities. The TGA investigates unlawful supply, manufacture, and advertising of therapeutic goods domestically. For major operations, both agencies execute search warrants jointly, sometimes alongside state police forces. The TGA also has civil penalty powers that allow it to pursue advertising and supply violations through the Federal Court without requiring criminal prosecution.

Individual states and territories have their own penalties for scheduled substance offences, creating a patchwork of consequences that varies by jurisdiction. For full detail on the legal framework and state-by-state penalties, see our dedicated Australia legality page.

The bottom line: Australia’s TGA enforcement uses a combination of scheduling changes, civil penalties through the Federal Court, border seizures via the ABF, and criminal prosecution through state law – making it the most multi-layered peptide enforcement system among Western nations.

Date	Event	Detail
2012-2013	Australian Crime Commission peptide investigation	Investigation into peptide use in professional sport triggers regulatory attention across Australasia
2013	Essendon AFL supplements scandal	Players administered thymosin beta-4; ultimately led to 34 players receiving 2-year suspensions from the Court of Arbitration for Sport in January 2016
2014	Melanotan II added to Schedule 4	Reclassified as prescription-only medicine due to adverse event reports and uncontrolled supply
2018	Federal Court proceedings commenced against Peptide Clinics Pty Ltd	Secretary of Department of Health alleges unlawful advertising and supply of compounded prescription-only therapeutic goods, including peptides, via website, Facebook, and Instagram
23 July 2019	Peptide Clinics – AUD 10 million penalty	Federal Court (Justice Jagot, 2019 FCA 1107) orders record penalty; Court finds “deliberate and reckless” pursuit of self-interest at expense of public health; Peptide Clinics subsequently liquidated
2022	BPC-157 added to WADA Prohibited List	Classified under Section S2 (peptide hormones, growth factors, related substances, and mimetics); triggers Australian awareness and scheduling review
July 2022 – 2024	BPC-157 import referrals accumulate	ABF refers 48 BPC-157 import interceptions to TGA; evidence cited in scheduling decision
April 2024	Victorian individual fined for peptide import	AUD 3,756 infringement notice for importing unapproved peptide without authority
1 June 2024	BPC-157 scheduled as S4 (world first)	Australia becomes the first country to specifically schedule BPC-157; TGA cites “high risk of misuse within athletic, fitness, wellness and anti-ageing consumer markets”
2024	GH secretagogues scheduled as a class	Ipamorelin (by name), GHRP-6, hexarelin, AOD-9604, HGH fragment, CJC-1295, and sermorelin captured under class scheduling
September 2025	Same Victorian individual fined again	3 additional infringement notices totalling AUD 11,268 for importing additional prescription-only medicines without approval
November 2025	Wegovy PBS recommendation	PBAC recommends subsidisation of semaglutide (Wegovy) for adults with established cardiovascular disease and obesity; listing expected mid-2026
February 2026	Melanotan II reclassified to S9	Moved from Schedule 4 to Schedule 9 (prohibited); possession now carries criminal penalties in all states; TGA cited 89 adverse event reports (2022-2025) including 2 melanoma diagnoses
26-31 March 2026	Melbourne AUD 2M PIED seizure	Joint ABF/TGA/Victoria Police; 10,000+ vials, 600 tablets; 3 arrested; 76 prior consignments identified since April 2025; 8-month investigation

The modern era of Australian peptide enforcement traces directly to the 2012-2013 Australian Crime Commission investigation into peptide use in professional sport. This investigation centred on the Essendon Football Club in the Australian Football League, where players were administered thymosin beta-4 as part of a supplements programme overseen by the club’s sports scientist, Stephen Dank. The affair became the most significant doping scandal in Australian sporting history.

The Anti-Doping Authority initially cleared the players, but the World Anti-Doping Agency appealed to the Court of Arbitration for Sport. In January 2016, CAS found that 34 current and former Essendon players had been administered thymosin beta-4, which was prohibited under WADA’s Section S2. All 34 received two-year suspensions. The case demonstrated that peptide offences could result in career-ending consequences for athletes and prompted the TGA to assess the broader regulatory gap through which unregulated peptides were reaching consumers.

The Essendon investigation also triggered Medsafe attention across the Tasman: New Zealand’s peptide scheduling timeline begins in 2013, the same year the ACC findings were published. The case effectively served as a catalyst for peptide regulation across the entire Australasian region.

The Federal Court’s AUD 10 million penalty against Peptide Clinics Pty Ltd remains the most significant peptide enforcement action in Australian history and one of the largest civil penalties ever imposed under the Therapeutic Goods Act. The proceedings, initiated by the Secretary of the Department of Health in 2018, alleged that Peptide Clinics advertised and sold compounded prescription-only therapeutic goods through its website, Facebook, and Instagram accounts.

Justice Jagot’s decision (2019 FCA 1107) found that Peptide Clinics had contravened the Act and the Therapeutic Goods Advertising Code on each day the advertisements appeared. The Court identified several aggravating factors: the company gave the impression that medical practitioners were involved in the business, misleading consumers into thinking those practitioners were acting in their best interests; the company “deliberately and recklessly pursued its own financial self-interest at the expense of its legal obligations and the interests of public health”; and the website made claims for peptides in contexts including anxiety, anti-ageing, bodybuilding, tanning, weight loss, premature ejaculation, hair loss, and insomnia relief.

The Court also ruled that even though Peptide Clinics was in liquidation and unable to pay the penalty, imposing it served an important deterrent purpose: “there is a significant public interest in the Court making declarations of contravening conduct on the public record in aid of deterrence.” This principle has been applied in subsequent TGA enforcement actions.

The bottom line: The Peptide Clinics case established that advertising peptides with therapeutic claims to consumers carries the risk of multi-million-dollar Federal Court penalties, regardless of whether the company survives long enough to pay them.

Australia has adopted the most aggressive scheduling posture of any Western nation toward individual peptides. Two decisions stand out as internationally significant.

BPC-157: World’s First Specific Scheduling (June 2024)

On 1 June 2024, Australia became the first country in the world to individually name and schedule BPC-157 under its national poisons standard. The TGA cited 48 import referrals from the ABF between July 2022 and 2024 and described BPC-157 as posing “a high risk of misuse within athletic, fitness, wellness and anti-ageing consumer markets.” The scheduling placed BPC-157 in Schedule 4 (Prescription Only), meaning possession without a prescription is a regulatory offence and importation without TGA authorisation is prohibited.

Melanotan II: Escalation to Schedule 9 (February 2026)

In February 2026, the TGA reclassified Melanotan II from Schedule 4 (Prescription Only) to Schedule 9 (Prohibited). Schedule 9 is the most restrictive classification in the Australian system – the same category as MDMA and heroin. The TGA’s decision was supported by 89 adverse event reports submitted between 2022 and 2025, including two confirmed melanoma diagnoses within 18 months of Melanotan II use, and concerns about non-selective melanocortin receptor activation and widespread social media promotion for non-medical use.

The class scheduling of growth hormone secretagogues – capturing ipamorelin, GHRP-6, hexarelin, AOD-9604, HGH fragment, CJC-1295, and sermorelin under a single entry – mirrors the group-entry approach used by New Zealand and reflects an enforcement strategy designed to prevent new analogues from exploiting scheduling gaps.

The bottom line: Australia has moved from targeted individual scheduling (BPC-157 in 2024) to criminal-tier prohibition (Melanotan II to S9 in 2026), establishing a precedent that compounds with widespread non-medical use may face the harshest possible classification.

The largest joint peptide enforcement operation in recent Australian history began in August 2025 when ABF officers intercepted 640 vials of performance and image enhancing drugs (PIEDs) across multiple air cargo consignments. Further investigation revealed that 76 similar consignments had allegedly been delivered to the same consignee since April 2025, indicating a sustained and coordinated importation network.

On 26 March 2026, ABF and TGA officers executed Commonwealth warrants at a commercial premises and residential address in Melbourne’s west. They seized more than 10,000 vials and 600 tablets, alongside cannabis seeds and multiple digital devices. A 47-year-old man was arrested and charged with two counts of importing Tier 1 Goods (PIEDs). On 31 March 2026, follow-up warrants led to seizures of additional PIEDs, cannabis, pepper sprays, and a taser, with a 46-year-old man and 42-year-old woman arrested and charged. All three appeared at Melbourne Magistrates Court and were granted bail.

The total estimated street value exceeded AUD 2 million. The TGA investigation specifically referenced “suspected unlawful supply, manufacture and advertising of unregistered therapeutic goods and prescription only medicines, including injectable peptide products” – confirming that peptides were a central focus of the operation, not incidental to a broader steroids investigation.

The TGA’s enforcement approach to individual importers follows a graduated escalation model. A case documented by Mills Oakley (a national law firm) illustrates the pattern: in April 2024, a Victorian individual received a single infringement notice of AUD 3,756 for importing an unapproved peptide without authority. In September 2025, the same individual received three additional infringement notices totalling AUD 11,268 for importing further prescription-only medicines without approval. The tripling of penalties for repeated non-compliance signals a deliberate deterrence strategy.

The TGA has also pursued court action beyond the peptide-specific Peptide Clinics case. Court proceedings were commenced against Evolution Supplements Australia and its sole director for alleged advertising breaches. A South Australian man faced criminal charges for dealing in counterfeit and unapproved medicines. These actions establish that enforcement extends beyond corporate entities to individual directors and sole traders.

The TGA’s civil penalty enforcement has concentrated disproportionately on advertising violations rather than supply or manufacturing offences. This reflects a strategic calculation: advertising is easier to document (website screenshots, social media archives, telephone recordings), generates large penalty amounts through the “per-day” contravention model (each day an advertisement is live counts as a separate contravention), and targets the most visible consumer-facing activity.

The Therapeutic Goods Advertising Code prohibits advertising prescription-only medicines directly to consumers. When a peptide vendor posts on Instagram, Facebook, or a company website that a product treats anxiety, promotes weight loss, improves hair growth, or enhances athletic performance, each day that post remains live constitutes a separate contravention. The Peptide Clinics case accumulated contraventions across website, Facebook, Instagram, and telephone channels – the “per-channel-per-day” model is why penalties reached AUD 10 million rather than the thousands-of-dollars range typical for one-off infringement notices.

This enforcement model has significant implications for any business selling peptides in Australia. Even a sole trader maintaining a website with therapeutic claims for an unregistered peptide product accumulates contraventions daily. The TGA does not need to prove the product was actually supplied – the advertising itself is the offence. Mills Oakley’s analysis notes that the TGA “has taken robust enforcement action over the past decade, imposing or securing pecuniary penalties ranging from a few thousand dollars up to $10 million for advertising breaches.”

The bottom line: In Australia, advertising a peptide with therapeutic claims is the single highest-risk commercial activity from an enforcement perspective, carrying cumulative daily penalties that can reach seven or eight figures.

Australia consistently ranks among the top countries globally for medicine seizure volumes during Operation Pangea. In the March 2026 iteration (Pangea XVIII), Australia placed third worldwide with 752,617 doses seized, behind only the UK (2,122,591 doses) and Colombia (1,473,434 doses). This ranking reflects both the TGA’s enforcement capacity and the volume of illegal medicines entering the Australian market.

Interpol’s global assessment identified peptides as an emerging category within the Operation Pangea scope, describing “synthetic substances promoted online for muscle growth, fat loss, and recovery” being sold as “research chemicals” or “cosmetic peptides” to circumvent detection. For the TGA, this international intelligence feeds directly into domestic scheduling decisions: the same border interception data used by Pangea operations contributed to the evidence base for BPC-157’s Schedule 4 classification.

Scheduling as Pre-emptive Enforcement

The TGA has adopted a strategy of scheduling substances before widespread harm materialises, using import interception data and adverse event reports as the evidence base. The BPC-157 scheduling cited border interception counts, not clinical trial failures. The Melanotan II reclassification cited adverse event reports and population-level non-medical use patterns. This approach gives the TGA enforcement tools (seizure, prosecution) that would not otherwise be available for unscheduled compounds.

Joint Operations as Standard Practice

The March 2026 Melbourne seizure exemplifies the shift toward multi-agency operations. The ABF handles border interception and import charges (Tier 1 Goods offences), the TGA handles therapeutic goods violations (advertising, supply, manufacture), and state police handle search warrant execution and physical arrests. This tripartite model makes it significantly harder for importation networks to evade enforcement by exploiting gaps between agencies.

Civil Penalties as Deterrence Infrastructure

The TGA has invested heavily in using civil penalty provisions introduced by Therapeutic Goods Act reforms. The civil penalty pathway allows the TGA to pursue large financial penalties through the Federal Court without the higher evidentiary standard required for criminal prosecution. The Peptide Clinics AUD 10 million penalty, while uncollectable from a liquidated company, serves as a permanent deterrent record. Mills Oakley’s analysis notes that “enforcement outcomes have generally been more severe for companies, reflecting their broader consumer reach and the greater risk to public health arising from non-compliant conduct.”

Enforcement Type	Example	Maximum / Actual Penalty
Federal Court civil penalty (advertising)	Peptide Clinics Pty Ltd (2019)	AUD 10 million (actual)
Infringement notice (individual import)	Victorian individual (2024)	AUD 3,756 (first offence), AUD 11,268 (repeat)
Criminal prosecution (import PIEDs)	Melbourne syndicate (March 2026)	3 charged, AUD 2M+ seizure value
Border seizure (ABF interception)	Routine operations (2023-2026)	847 shipments seized Q1 2026; seizure and destruction
S9 possession (Melanotan II, post-Feb 2026)	No public case yet	Criminal offence; penalties vary by state (imprisonment possible)

The Wegovy PBS listing (expected mid-2026) will expand legitimate access to semaglutide while simultaneously increasing enforcement pressure on compounded and grey-market alternatives. The tirzepatide PBS re-entry remains uncertain following a rejected cost-effectiveness application. Any expansion of the PBS-listed GLP-1 supply will narrow the market for unapproved peptide alternatives, potentially concentrating remaining demand on non-GLP-1 research peptides and triggering further scheduling reviews.

The TGA updates the Poisons Standard multiple times per year. The Advisory Committee on Chemicals Scheduling reviews compounds based on evolving adverse event data, border interception trends, and international harmonisation. Any peptide that accumulates sufficient adverse event reports or import interception counts is a candidate for scheduling review. The December 2025 New Zealand group scheduling decision may also influence TGA thinking, as trans-Tasman harmonisation is a recurring consideration for both regulators.

The bottom line: The TGA’s enforcement trajectory is toward more scheduling, higher penalties, and more joint operations with the ABF – with no signals of relaxation in any category.